Aiming TILs at Melanoma, Cervical Cancer.
Findings from two phase II trials indicate that tumor-infiltrating lymphocyte therapy may prove an effective option for advanced melanoma and cervical cancer. The treatment was well tolerated, with durable responses seen even in patients whose disease was refractory to standard treatment.